News Center
NEWS CENTER

Supplementation with the NAD+ precursors NMN or NR holds promise for effectively reducing the risk of keratinocyte carcinoma.


Classification: Industry News

Publication:2022-10-21 09:03

Compared with NAM, oral NMN and NR are more effective at elevating NAD+ levels and exhibit better safety and tolerability. For dermatologists, they represent a potential therapeutic strategy for reducing the risk of keratinocyte carcinoma; however, their clinical application still requires extensive validation through large-scale clinical studies.

Nicotinamide adenine dinucleotide (NAD+) is a research hotspot among scientists worldwide. Most researchers believe that NAD+ levels are closely linked to age‑related chronic diseases, such as cancer, obesity, hypertension, and diabetes.

 

 

Keratinocyte carcinoma (KC) is the most common malignancy among individuals with fair skin, primarily comprising basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). Recently, U.S. scientists published an article in the journal J DRUGS DERMATOL arguing that supplementation with the NAD precursors NMN and NR may reduce the risk of keratinocyte carcinoma.

 

 

The authors contend that nicotinamide (NAM), as a precursor to NAD+, has been shown by Choy B and other researchers to reduce the incidence of keratinocyte carcinoma. However, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR)—also precursors in NAD+ biosynthesis—may represent even more effective supplements for lowering the incidence of keratinocyte carcinoma.

 

Oral administration of NMN and NR can effectively elevate NAD+ levels.

In 2018, Sinclair et al. demonstrated that, compared with NAM, oral administration of NMN and NR increased NAD+ levels in both blood and liver in humans and mice, respectively, suggesting that NMN and NR are more efficient at synthesizing NAD+.

 

NMN and NR are safe and better tolerated.

NMN and NR supplements have been widely used in both humans and animals, with no reports of toxicity or serious adverse effects to date. In one clinical study, 25 postmenopausal women with prediabetes were given an oral NMN supplement at a dose of 250 mg/day, and NMN was found to enhance muscle insulin sensitivity without causing any adverse events. A second clinical study examined the effects of NMN supplementation on aerobic capacity in runners; 36 participants received NMN at doses of 300 mg/day (n=12), 600 mg/day (n=12), or 1,200 mg/day (n=12), and no side effects or adverse events were reported across all dosage groups. Although the U.S. Food and Drug Administration (FDA) has not yet approved these two compounds for use in dietary supplements, NMN and NR supplements are readily available online, and many consumers have begun taking them at doses ranging from 500 to 1,000 mg per day, with no adverse events observed.

 

Compared with NAM, oral NMN and NR are more effective at elevating NAD+ levels and exhibit better safety and tolerability. For dermatologists, they represent a potential therapeutic strategy to reduce the risk of keratinocyte carcinoma; however, their clinical application still requires extensive validation through large-scale clinical studies.

 

References:

[1]. Kahn B, Borrelli M, Libby T. A Narrative Review of Nicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside and Nicotinamide Mononucleotide for Keratinocyte Carcinoma Risk Reduction. J Drugs Dermatol. 2022 Oct 1;21(10):1129-1132. doi: 10.36849/JDD.6870. PMID: 36219044.


Leave a Message Online

yzm
Submit